New pulmonary delivery platform based on chitosan nanocapsules with potential application in gene therapy

  1. Fernández Paz, Estefenía
unter der Leitung von:
  1. Carmen Remuñán López Doktormutter

Universität der Verteidigung: Universidade de Santiago de Compostela

Fecha de defensa: 30 von März von 2022

Gericht:
  1. Mónica López Fanarraga Präsident/in
  2. Marcos García Fuentes Sekretär
  3. Florentina Niuris Acosta Contreras Vocal
Fachbereiche:
  1. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéutica

Art: Dissertation

Teseo: 710153 DIALNET lock_openMINERVA editor

Zusammenfassung

Gene therapy offers hope of cure for rare and other serious diseases that currently have no established effective treatments. It has become a valuable therapeutic strategy for congenital or acquired genetic lung diseases, such as alpha1-antitrypsin deficiency, infections and some types of lung cancer, among others. In this Thesis work, a new pulmonary delivery platform consisting of mannitol microspheres (Ma MS) containing chitosan-based nanocapsules (CS-based NCs) loaded with the model plasmid pCMV-betaGal is proposed for its direct delivery to the lung. The designed micro-nanostructures have suitable aerodynamic properties, are biocompatible with the A549 lung cell line and are distributed in the deep lung, producing transfection.